Drug/Device Combo Hits Phase III Endpoint
AcelRx Moving Sublingual Analgesic Toward Goal Line
By Marie Powers
Friday, November 16, 2012
After toiling in the trenches for nearly five years, specialty pharma AcelRx Pharmaceuticals Inc. reported a breakthrough with positive top-line data from the first Phase III study of its lead product candidate, the sublingual Sufentanil NanoTab PCA System (ARX-01), compared to intravenous morphine in postoperative pain.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.